Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Sponsor: Neurocrine Biosciences
Summary
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
Official title: A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
850
Start Date
2025-04-16
Completion Date
2030-05
Last Updated
2026-04-23
Healthy Volunteers
No
Conditions
Interventions
NBI-1065845
NBI-1065845 tablets
Locations (87)
Neurocrine Clinical Site
Huntsville, Alabama, United States
Neurocrine Clinical Site
Bryant, Arkansas, United States
Neurocrine Clinical Site
Little Rock, Arkansas, United States
Neurocrine Clinical Site
Glendale, California, United States
Neurocrine Clinical Site
Los Angeles, California, United States
Neurocrine Clinical Site
Oceanside, California, United States
Neurocrine Clinical Site
Orange, California, United States
Neurocrine Clinical Site
Pico Rivera, California, United States
Neurocrine Clinical Site
San Diego, California, United States
Neurocrine Clinical Site
Upland, California, United States
Neurocrine Clinical Site
Cromwell, Connecticut, United States
Neurocrine Clinical Site
Farmington, Connecticut, United States
Neurocrine Clinical Site
Hollywood, Florida, United States
Neurocrine Clinical Site
Maitland, Florida, United States
Neurocrine Clinical Site
Maitland, Florida, United States
Neurocrine Clinical Site
Miami, Florida, United States
Neurocrine Clinical Site
Miami Gardens, Florida, United States
Neurocrine Clinical Site
Palm Bay, Florida, United States
Neurocrine Clinical Site
Tampa, Florida, United States
Neurocrine Clinical Site
Tampa, Florida, United States
Neurocrine Clinical Site
Atlanta, Georgia, United States
Neurocrine Clinical Site
Gaithersburg, Maryland, United States
Neurocrine Clinical Site
Boston, Massachusetts, United States
Neurocrine Clinical Site
Watertown, Massachusetts, United States
Neurocrine Clinical Site
O'Fallon, Missouri, United States
Neurocrine Clinical Site
Saint Charles, Missouri, United States
Neurocrine Clinical Site
Cedarhurst, New York, United States
Neurocrine Clinical Site
Mount Kisco, New York, United States
Neurocrine Clinical Site
New York, New York, United States
Neurocrine Clinical Site
New York, New York, United States
Neurocrine Clinical Site
The Bronx, New York, United States
Neurocrine Clinical Site
Avon Lake, Ohio, United States
Neurocrine Clinical Site
Edmond, Oklahoma, United States
Neurocrine Clinical Site
Philadelphia, Pennsylvania, United States
Neurocrine Clinical Site
Dallas, Texas, United States
Neurocrine Clinical Site
Houston, Texas, United States
Neurocrine Clinical Site
Richmond, Texas, United States
Neurocrine Clinical Site
Stafford, Texas, United States
Neurocrine Clinical Site
The Woodlands, Texas, United States
Neurocrine Clinical Site
Everett, Washington, United States
Neurocrine Clinical Site
Alken, Belgium
Neurocrine Clinical Site
Mechelen, Belgium
Neurocrine Clinical Site
Plovdiv, Bulgaria
Neurocrine Clinical Site
Sofia, Bulgaria
Neurocrine Clinical Site
Sofia, Bulgaria
Neurocrine Clinical Site
Sofia, Bulgaria
Neurocrine Clinical Site
Sofia, Bulgaria
Neurocrine Clinical Site
Varna, Bulgaria
Neurocrine Clinical Site
Zagreb, Croatia
Neurocrine Clinical Site
Zagreb, Croatia
Neurocrine Clinical Site
Pilsen, Czechia
Neurocrine Clinical Site
Prague, Czechia
Neurocrine Clinical Site
Prague, Czechia
Neurocrine Clinical Site
Prague, Czechia
Neurocrine Clinical Site
Prague, Czechia
Neurocrine Clinical Site
Tallinn, Estonia
Neurocrine Clinical Site
Kuopio, Finland
Neurocrine Clinical Site
Oulu, Finland
Neurocrine Clinical Site
Tampere, Finland
Neurocrine Clinical Site
Budapest, Hungary
Neurocrine
Sigulda, Lativa, Latvia
Neurocrine Clinical Site
Jelgava, Latvia
Neurocrine Clinical Site
Liepāja, Latvia
Neurocrine Clinical Site
Kaunas, Lithuania
Neurocrine Clinical Site
Amsterdam, Netherlands
Neurocrine Clinical Site
Groningen, Netherlands
Neurocrine Clinical Site
Leiden, Netherlands
Neurocrine Clinical Site
Bełchatów, Poland
Neurocrine Clinical Site
Bialystok, Poland
Neurocrine Clinical Site
Bialystok, Poland
Neurocrine Clinical Site
Bydgoszcz, Poland
Neurocrine Clinical Site
Gdansk, Poland
Neurocrine Clinical Site
Gdansk, Poland
Neurocrine Clinical Site
Grudziądz, Poland
Neurocrine Clinical Site
Katowice, Poland
Neurocrine Clinical Site
Craiova, Romania
Neurocrine Clinical Site
Bojnice, Slovakia
Neurocrine Clinical Site
Bratislava, Slovakia
Neurocrine Clinical Site
Košice, Slovakia
Neurocrine Clinical Site
Rimavská Sobota, Slovakia
Neurocrine Clinical Site
Svidník, Slovakia
Neurocrine Clinical Site
Vranov nad Topľou, Slovakia
Neurocrine Clinical Site
Gothenburg, Sweden
Neurocrine Clinical Site
Lund, Sweden
Neurocrine Clinical Site
Stockholm, Sweden
Neurocrine Clinical Site
Sheffield, South Yorkshire, United Kingdom
Neurocrine Clinical Site
London, United Kingdom